Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 10/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 10/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477968 | 1.00 | MAP3K7 (0.35) | MAP3K7TAB1CCNCCDK8 | |
| Cis-Urocanic Acid SCHEMBL2265413 | 0.85 | KDM4E (0.40) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL2265408 | 0.85 | KDM4E (0.40) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL2249970 | 0.83 | — | — | |
| Cis-Urocanic Acid SCHEMBL1311341 | 0.82 | KDM4E (0.43) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL1755678 | 0.82 | KDM4E (0.43) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL19031717 | 0.82 | KDM4E (0.43) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL15417 | 0.82 | KDM4E (0.43) | MAP3K7TAB1 | |
| Cis-Urocanic Acid SCHEMBL15418 | 0.82 | KDM4E (0.43) | MAP3K7TAB1 | |
| SCHEMBL3321813 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591637-B2 | Plating catalyst and method | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2013-11-26 | — | — | US | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| CN-1338456-A | Benzodiazepine compound containing imidazole propionamido and preparation method and application thereof | INST OF MEDICAL MATERIALS CHIN (CN) | 2002-03-06 | — | — | CN | claimed |
| CN-118974066-A | EGFR degrading agent | 北京泰德制药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023198180-A1 | EGFR DEGRADATION AGENT | 北京泰德制药股份有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| CN-1338456-A | Benzodiazepine compound containing imidazole propionamido and preparation method and application thereof | INST OF MEDICAL MATERIALS CHIN (CN) | 2002-03-06 | — | — | CN | disclosed |
| US-4931471-A | Amides of paramethoxycinnamic and utilization thereof as solar filters | UNIVERSITE LOUIS PASTEUR (FR) | 1990-06-05 | — | — | US | disclosed |
| US-3929819-A | Urocanic acid amide derivatives | AJINOMOTO KK | 1975-12-30 | — | — | US | disclosed |
| US-3929819-A | Urocanic acid amide derivatives | AJINOMOTO KK | 1975-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | MAP3K7 974/4885TAB1 803/4885CCNC 1632/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | MAP3K7 974/4885TAB1 803/4885CCNC 1632/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | MAP3K7 2895/4885TAB1 4090/4885CCNC 4120/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | MAP3K7 3898/4885TAB1 4365/4885CCNC 4366/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | MAP3K7 4003/4885TAB1 4572/4885CCNC 4458/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | MAP3K7 974/4885TAB1 803/4885CCNC 1632/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | MAP3K7 3885/4885TAB1 4345/4885CCNC 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.